2025年岁末,国产创新药出海热潮再起!涉及先声药业、荃信生物等

制药网
Dec 23, 2025

近年来,中国创新药企通过 BD 对外授权或转让(License-out)模式实现“出海”的案例呈现出爆发式增长的态势,已成为中国医药产业融入全球创新体系的最重要途径之一。2025年进入12月,国产创新药出海热潮再次掀起。如12月22日,先声药业发布公告,与Ipsen签订了独家授权许可协议,涉及其开发的抗体药物偶联物SIM0613。先声药业有权收取最高达10.6亿美元的款项,其中包括4500万美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10